Stablecoins are here to stay says BlackRock
EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ:SRDX), a medical device and diagnostic technology provider with a market capitalization of $440 million and impressive gross margins of 75%, has announced the commercial release of the Pounce™ XL Thrombectomy System, designed for the endovascular removal of clots in peripheral arteries. The Pounce™ XL is the latest addition to the company’s suite of thrombectomy systems and is indicated for arteries ranging from 5.5 to 10 mm in diameter. According to InvestingPro analysis, the company maintains a strong financial health score of GOOD, with liquid assets significantly exceeding short-term obligations.
The Pounce™ XL system joins the existing Pounce™ and Pounce LP (Low-Profile) systems, which cater to arteries of 3.5 to 6 mm and 2 to 4 mm, respectively. Collectively, the Pounce™ Thrombectomy Platform can now address a wide range of vessel diameters from 2 to 10 mm, offering a comprehensive solution for the removal of arterial thrombi and emboli in the lower and upper extremities.
This fully mechanical platform utilizes proprietary dual-basket technology to capture and remove clots without the need for thrombolytics, aspiration, or capital equipment, thereby minimizing blood loss and reducing the risk of distal embolization and vessel wall damage.
The Pounce XL Thrombectomy System has undergone a limited market release since January 2025. Dr. Anna Marjan, a vascular surgeon at Allina Health Mercy Hospital, has reported successful removal of substantial clot material from a patient’s infrarenal aorta and common iliac arteries using the system, highlighting the potential benefits of avoiding surgical cutdown.
Interim data from the PROWL registry, a study of the Pounce Thrombectomy Platform, has shown an average use time of 20.3 minutes and a high rate of patients requiring no further clot removal treatment post-use. The study also reported a low incidence of device-related adverse events.
Gary Maharaj, President and CEO of Surmodics, emphasized the system’s simplicity and effectiveness, as well as its growing clinical adoption and the benefits it provides to patients with limb ischemia. While InvestingPro data shows the company currently operates at a loss with a high EBITDA multiple, its moderate debt levels and strong current ratio of 5.45x suggest financial stability. Unlock deeper insights with InvestingPro’s comprehensive research report, featuring detailed analysis of Surmodics’ financial health and growth prospects.
The Pounce Thrombectomy Platform, including the Pounce™ XL, is FDA-cleared and represents Surmodics’ commitment to addressing unmet clinical needs in vascular intervention. With annual revenues of $125 million and several additional InvestingPro Tips available, investors seeking detailed analysis can access the full financial picture through an InvestingPro subscription. The information in this article is based on a press release statement from Surmodics, Inc.
In other recent news, Surmodics Inc. is preparing to defend its planned merger with GTCR LLC in court after the Federal Trade Commission (FTC) challenged the acquisition. The merger, valued at approximately $627 million, would see GTCR acquiring all outstanding shares of Surmodics for $43.00 per share in cash. This transaction, once completed, will result in Surmodics becoming a private entity, with its shares delisted from the Nasdaq Global Select Market. Surmodics shareholders had previously approved the merger, but the company is now engaged in legal proceedings to address the FTC’s opposition.
Additionally, at Surmodics’ recent Annual Meeting of Shareholders, several key proposals were approved. Gary R. Maharaj was re-elected as a Class II director, and the proposal to set the number of directors at five was also passed. Furthermore, Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year 2025. Shareholders also approved the compensation of Surmodics’ named executive officers in an advisory vote. These developments indicate continued shareholder support for the company’s governance practices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.